Pibrentasvir

A hepatitis C virus NS5A inhibitor

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥625.00

500.00

- +
10mg

￥912.00

730.00

- +
25mg

￥1812.00

1450.00

- +
50mg

￥2887.00

2310.00

- +
100mg

￥4575.00

3660.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajci23150
CAS: 1353900-92-1
别名: 哌仑他韦
分子式: C57H65F5N10O8
分子量: 1113.18
纯度: >98%
溶解度: DMF: 25 mg/ml,DMSO: 20 mg/ml,Ethanol: 10 mg/ml
储存: Store at -20°C
库存: 现货

Background

Pibrentasvir is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC50s ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.

Pibrentasvir inhibits HCV genotype 1a-H77, 1b-Con1, and 2a-JFH-1 subgenomic replicons with 50% effective concentrations (EC50s) of 1.8, 4.3, and 5.0 pM, respectively. The antiviral activity of Pibrentasvir is attenuated 35- to 47-fold in the presence of 40% human plasma through sequestration of compound due to plasma protein binding. Pibrentasvir retains full activity against all of the genotype 1a and 1b single-position NS5A substitutions tested, except Y93H and Y93N in genotype 1a, which confers a ≤7-fold increase in EC50 to Pibrentasvir[1].

[1]. Ng TI, et al. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02558-16.

Protocol

Cell experiment:

The inhibitory effect of Pibrentasvir on HCV replication in replicon cells is determined in Dulbecco's modified Eagle's medium (DMEM) containing 5% fetal bovine serum with or without 40% human plasma. The cells are incubated with Pibrentasvir for 3 days and are subsequently lysed and processed according to the manufacturer's instructions to measure luciferase reporter activity using a Victor II luminometer. The 50% effective concentration (EC50) value is calculated using nonlinear regression curve fitting to the four-parameter logistic equation in software[1].

参考文献: